Subscribe to our Newsletters !!
Anemones Sea have a striking beauty and the abilit
Quantitative LC�
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceutica
Alembic Pharmaceuticals Limited (Alembic) today an
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-look
According to reports, the Drugs Controller General of India has approved a trial of mixing two COVID-19 vaccines — Covishield & Covaxin.
The mix-and-match study will be conducted by Christian Medical College, Vellore, India Today reported.
The nod is granted approximately 11 days after the Subject Expert Committee of the CDSCO (Central Drugs Standard Control Organisation), recommended that a mix-and match trial be allowed.
The SEC panel also recommended that Bharat Biotech be allowed to conduct a study on interchangeability between its Covaxin vaccine and the currently under-trial adenoviral intramuscular vaccine candidate BBV154. The report stated that DCGI has yet to make a decision on this matter.
Meanwhile, a recent study by ICMR involving 98 people, 18 of whom had inadvertently received Covishield as first dose and Covaxin as the second in Uttar Pradesh showed that combining these two COVID-19 vaccines elicited better immunogenicity than two doses of the same vaccine.
